Last edited:
From his wiki page:
Robbie died on January 13, 2023, aged 60, from pancreatic cancer.
All that bad ass riding and jumping and pancreatic cancer takes him out so young. Best wishes to his family. I wonder how the last 10 or so years of his life has been dealing with the pain of all the broken bones and injuries from his jumps and stunts. I understand this, I've had a few hard crashes on my dirt bike and feel it everyday.
Robbie died on January 13, 2023, aged 60, from pancreatic cancer.
All that bad ass riding and jumping and pancreatic cancer takes him out so young. Best wishes to his family. I wonder how the last 10 or so years of his life has been dealing with the pain of all the broken bones and injuries from his jumps and stunts. I understand this, I've had a few hard crashes on my dirt bike and feel it everyday.
mRNA tech is in its infancy as a new tool in the battle Vs Cancer. Clinical trials are out already-- to be able to have the body recognize the cancer cells as foreign then take them out . AND for cancer survivors to give them an mRNA vac that prevents (decreases the probability of)its recurrence. This tech is WAY WAY more specific than current immunotherapies. Potential game changer-therapeutic and preventative .....may have to give Trump the Nobel Peace Prize in Medicine if this pans fellas 
www.telegraph.co.uk
RIP
Clinical advances and ongoing trials of mRNA vaccines for cancer treatment
Years of research exploring mRNA vaccines for cancer treatment in preclinical and clinical trials have set the stage for the rapid development of mRNA vaccines during the COVID-19 pandemic. Therapeutic cancer vaccines based on mRNA are well tolerated, and the inherent advantage in ease of...
www.thelancet.com
Cancer vaccine trials to begin in Britain this year
Government deal with BioNTech enables trials of jabs designed to fight established disease and advanced tumours
www.telegraph.co.uk
RIP
posted , gotta be yr ago that they opened a sleeping giant with mRNA tech ,that its next target to be at cancer , well...to add from my previous post
clever MRK !!!!!!
pharma giant Merck has paid Moderna $250 million to co-develop and commercialize a promising personalized cancer vaccine based on its mRNA technology.
The background: In 2016,pharma giant Merck gave Moderna $200 million to research and develop personalized cancer vaccines based on mRNA. At the time, it was a big bet — mRNA technology had yet to be translated into any approved vaccine.
Part of the original agreement specified that if Moderna could complete proof-of-concept studies of mRNA-based personalized cancer vaccines in humans, Merck had the option to pay an undisclosed amount to co-develop and commercialize the shots with Moderna.
What’s new? Merck is now exercising its option on mRNA-4157, a personalized cancer vaccine in a phase 2 clinical trial for skin cancer. It’s being studied in combination with Merck’s cancer treatment Keytruda, a humanized monoclonal antibody.
“This long-term collaboration combining Merck’s expertise in immuno-oncology with Moderna’s pioneering mRNA technology has yielded a novel tailored vaccine approach,” said Eliav Barr, head of global clinical development and CMO of Merck Research Laboratories.
A personalized cancer vaccine: Moderna’s cancer vaccine works differently than most vaccines because it’s designed to treat an existing disease rather than prevent it entirely. It’s also personalized for each patient, while other shots are typically mass produced and distributed to the population.
To create each vaccine, Moderna takes a sample of a patient’s tumor. It then uses genetic sequencing technology to identify proteins in the tissue called “neoantigens.” These proteins are found only on the surface of cancer cells, and they are unique to each person’s tumor.
Moderna then uses its mRNA technology to create a vaccine that instructs cells to make up to 34 of the cancer’s specific neoantigens, which are shown off to immune cells as potential targets. The idea is that this will trigger an immune response against the neoantigens, helping the immune system identify and attack cancerous cells.
Looking ahead: For Moderna’s ongoing phase 2 trial of mRNA-4157, 157 patients with high-risk melanoma had their tumors removed via surgery.
Some of the patients were then given nine doses of a personalized cancer vaccine and a dose of Keytruda every three weeks for approximately one year or until their melanoma came back. The rest were given just a dose of Keytruda every three weeks for one year.
The trial’s primary endpoint is recurrence-free survival, and given Merck’s new investment in the vaccine, it seems reasonable to expect positive results.
....................
big pharma going to throw the kitchen sink at this. We get a clearer pic of its efficacy or lack thereof ,id say by late 2024....looking good early , its real early
clever MRK !!!!!!
pharma giant Merck has paid Moderna $250 million to co-develop and commercialize a promising personalized cancer vaccine based on its mRNA technology.
The background: In 2016,
pharma giant Merck gave Moderna $200 million to research and develop personalized cancer vaccines based on mRNA. At the time, it was a big bet — mRNA technology had yet to be translated into any approved vaccine.Part of the original agreement specified that if Moderna could complete proof-of-concept studies of mRNA-based personalized cancer vaccines in humans, Merck had the option to pay an undisclosed amount to co-develop and commercialize the shots with Moderna.
What’s new? Merck is now exercising its option on mRNA-4157, a personalized cancer vaccine in a phase 2 clinical trial for skin cancer. It’s being studied in combination with Merck’s cancer treatment Keytruda, a humanized monoclonal antibody.
“This long-term collaboration combining Merck’s expertise in immuno-oncology with Moderna’s pioneering mRNA technology has yielded a novel tailored vaccine approach,” said Eliav Barr, head of global clinical development and CMO of Merck Research Laboratories.
A personalized cancer vaccine: Moderna’s cancer vaccine works differently than most vaccines because it’s designed to treat an existing disease rather than prevent it entirely. It’s also personalized for each patient, while other shots are typically mass produced and distributed to the population.
To create each vaccine, Moderna takes a sample of a patient’s tumor. It then uses genetic sequencing technology to identify proteins in the tissue called “neoantigens.” These proteins are found only on the surface of cancer cells, and they are unique to each person’s tumor.
Moderna then uses its mRNA technology to create a vaccine that instructs cells to make up to 34 of the cancer’s specific neoantigens, which are shown off to immune cells as potential targets. The idea is that this will trigger an immune response against the neoantigens, helping the immune system identify and attack cancerous cells.
Looking ahead: For Moderna’s ongoing phase 2 trial of mRNA-4157, 157 patients with high-risk melanoma had their tumors removed via surgery.
Some of the patients were then given nine doses of a personalized cancer vaccine and a dose of Keytruda every three weeks for approximately one year or until their melanoma came back. The rest were given just a dose of Keytruda every three weeks for one year.
The trial’s primary endpoint is recurrence-free survival, and given Merck’s new investment in the vaccine, it seems reasonable to expect positive results.
....................
big pharma going to throw the kitchen sink at this. We get a clearer pic of its efficacy or lack thereof ,id say by late 2024....looking good early , its real early
